TPG acquires minority stake in Sai LIfe Sciences

Currently serving seven out of the top 15 global pharmaceutical companies, Sai Life Sciences is well-positioned to launch of 25 new medicines by global innovator partners through 2025.

TPG, a global alternative asset firm, today announced it acquired a minority stake in Sai Life Sciences, a city-based drug discovery, development and manufacturing service providers, for an undisclosed sum.

A press release said TPG Capital Asia acquired the equity stake from Tata Capital. In the release, chief executive officer of Sai Life Sciences, Krishna Kanumuri said the investment from TPG reflects the strength, quality and growth potential of the drug company.

With its headquartered here, Sai Life Sciences is an integrated provider of drug discovery, development, and manufacturing solutions for innovator pharmaceutical and biotechnology companies, it said.

Currently serving seven out of the top 15 global pharmaceutical companies, Sai Life Sciences is well-positioned to launch of 25 new medicines by global innovator partners through 2025.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)